Robert Gould, Fulcrum Therapeutics CEO
August 11, 2020 10:37 AM EDTUpdated 03:45 PM
R&D

Ful­crum stum­bles in PhII of old GSK drug, send­ing shares tum­bling

Jason Mast

Editor

In­vestors are sell­ing off shares of Ful­crum Ther­a­peu­tics $FULC af­ter their lead drug failed in a Phase II tri­al.

The com­pa­ny, found­ed three years …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos

Post-Hoc: Phar­ma CEOs' al­ter­na­tive re­al­i­ty with Trump

Sanofi, Te­va bol­ster case for IBD drug with Phase 2 da­ta, de­spite po­ten­tial com­pe­ti­tion

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times